Early Alert: Automated Compounding System Issue from Omnicell
The FDA issued an alert regarding Omnicell’s i.V.Station automated compounding systems, noting that certain labels may fail to be detected by the system. This failure can result in the production of mislabeled sterile filled syringes.
This affects hospital pharmacies and compounding facilities utilizing Omnicell i.V.Station automated systems, as well as personnel responsible for medication labeling and verification.
Mislabeled sterile syringes present a significant clinical risk, potentially leading to medication errors at the point of care. From a regulatory perspective, this indicates a mechanical or sensor-related failure in label detection protocols, which may necessitate immediate manufacturer intervention, field corrections, or software/hardware updates to ensure labeling accuracy and patient safety.
QA and pharmacy leadership should immediately verify label compatibility with on-site i.V.Station systems. Establish a secondary manual verification step for syringe labels until the detection failure is resolved to prevent medication errors. Department heads should document these interim controls within the facility's risk management file.
Certain labels used with i.V.Station automated compounding systems may not be detected, leading to mislabeled sterile filled syringes
Open in openFDA / FDA.gov